Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 148
Filtrar
1.
BMC Infect Dis ; 21(1): 475, 2021 May 25.
Artículo en Inglés | MEDLINE | ID: mdl-34034659

RESUMEN

BACKGROUND: Chickenpox is a highly contagious disease caused by the varicella zoster virus (VZV), and in infants, adolescents, adults, pregnant women, and the immunocompromised it can be serious. The best way to prevent chickenpox is immunization with the varicella vaccine. Protective levels of antibodies induced by the varicella vaccine decline over time, but there is currently no formal recommendation for testing anti-varicella zoster virus (VZV) IgG levels in immunized healthcare workers (HCWs). METHODS: The aims of this study were to evaluate the seroprevalence of circulating anti-VZV IgG in a sample a sample of students and residents of the medical school of the University of Bari, the long-term immunogenicity of the varicella vaccine, and the effectiveness of a strategy consisting of a third vaccine booster dose. The study population was screened as part of a biological risk assessment conducted between April 2014 and October 2020. A strategy for the management of non-responders was also examined. RESULTS: The 182 students and residents included in the study had a documented history of immunization (two doses of varicella vaccine). The absence of anti-VZV IgG was determined in 34% (62/182; 95%CI = 27.2-41.4%), with serosusceptibility more common among males than females (p < 0.05). After a third varicella dose, seroconversion was achieved in 100% of this previously seronegative group. No serious adverse events were recorded. CONCLUSIONS: One-third of the study population immunized against VZV lacked a protective antibody titer, but a third dose of vaccine restored protection. Since it is highly unlikely that VZV will be eliminated in the immediate future, the loss of immunity in a substantial portion of the population implies a risk of varicella outbreaks in the coming years. Screening for varicella immunity in routine assessments of the biological risk of medical students and HCWs may help to prevent nosocomial VZV infections.


Asunto(s)
Anticuerpos Antivirales/sangre , Vacuna contra la Varicela/inmunología , Varicela/epidemiología , Varicela/prevención & control , Brotes de Enfermedades/prevención & control , Personal de Salud , Herpesvirus Humano 3/inmunología , Inmunización Secundaria/métodos , Vacunación/métodos , Adolescente , Adulto , Anticuerpos Antivirales/inmunología , Varicela/sangre , Varicela/virología , Vacuna contra la Varicela/administración & dosificación , Infección Hospitalaria/epidemiología , Infección Hospitalaria/prevención & control , Femenino , Humanos , Inmunogenicidad Vacunal , Inmunoglobulina G/sangre , Italia/epidemiología , Masculino , Estudios Retrospectivos , Estudios Seroepidemiológicos , Resultado del Tratamiento , Adulto Joven
2.
Rev. Asoc. Esp. Espec. Med. Trab ; 29(2): 23-28, jun. 2020. tab, graf
Artículo en Español | IBECS | ID: ibc-193750

RESUMEN

INTRODUCCIÓN Y OBJETIVOS: Garantizar la seguridad y salud de los estudiantes de enfermería que realizan prácticas en el hospital ofreciéndoles vacunación hasta alcanzar el nivel inmunológico de protección necesario. METODOLOGÍA: Revisión y recogida de datos de las historias clínico-laborales de 182 estudiantes de la Escuela de Enfermería de Sacyl en Zamora (2016-2019). RESULTADOS: Todos acreditan estar vacunados según calendario oficial. Tras primera serología, el 31,6% no presenta inmunidad frente a la triple vírica, el 2,15% frente a la varicela y el 86,9% frente a la vacuna de la hepatitis B. El 7,1% resultó no respondedor frente a la vacuna de la hepatitis B tras segunda pauta vacunal completa. CONCLUSIONES: La realización de la serología en el cribado prevacunación permite revacunar a aquellos que no presentan inmunización así como detectar aquellos casos no respondedores que tendrán un manejo adecuado si ocurre un accidente con exposición a una fuente de alto riesgo


INTRODUCTION AND OBJETIVES: Ensure the safety and health of nursing students who practice in the hospital by providing them with vaccinations up to the necessary immune protection level. METHODOLOGY: Review and data collection from the clinical- workplace histories of 182 students of the Sacyl School of Nursing in Zamora (2016-2019). RESULTS: All of them certify to be vaccinated according to official calendar. After the first serology, 31.6% did not have immunity against the triple virus, 2.15% against chickenpox and 86.9% against the hepatitis B vaccine. 7.1% were not responding to the hepatitis B vaccine after the second complete vaccination. CONCLUSION: The realization of serology in the screening allows to revaccinate those who don't present immunization, as well as detect those non-responders who will have adequate management if an accident with exposure to a high-risk source occurs


Asunto(s)
Humanos , Estudiantes de Enfermería/estadística & datos numéricos , Vacunación/estadística & datos numéricos , Vacunas contra Hepatitis B/sangre , Varicela/sangre , Varicela/inmunología , Vacunas contra Hepatitis B/inmunología , Salud Laboral/estadística & datos numéricos , España
3.
Cad Saude Publica ; 36(1): e00149119, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-31967286

RESUMEN

Varicella in adults and immunocompromised patients can be severe. The clinical diagnosis of varicella has high accuracy and the history of disease has a high positive predictive value for protection. A significant portion of adults, however, cannot remember if they have had varicella, especially older individuals. We conducted a cross-sectional study to determine the seroprevalence of varicella protective antibodies titers in adults with no clinical history of disease, attended at a Reference Center for Special Immunobiologicals and Travel Medicine in Rio de Janeiro (Brazil). Titration of immunoglobulin G (IgG) antibodies to varicella-zoster was determined by chemiluminescence immunoassay. Among 140 adults without history of varicella, 92% had protective antibody titers. We concluded that seroprevalence of varicella-zoster protection was very high in adults with negative history of disease and the use of serology before vaccination reduced significantly unnecessary vaccine and immunoglobulin use.


Asunto(s)
Varicela/epidemiología , Herpesvirus Humano 3/inmunología , Inmunoglobulina G/sangre , Adulto , Anticuerpos Antivirales/sangre , Brasil/epidemiología , Varicela/sangre , Varicela/prevención & control , Vacuna contra la Varicela , Estudios Transversales , Humanos , Mediciones Luminiscentes , Prevalencia , Estudios Seroepidemiológicos
4.
J Crohns Colitis ; 14(5): 608-616, 2020 Jun 19.
Artículo en Inglés | MEDLINE | ID: mdl-31889176

RESUMEN

INTRODUCTION: Increased risk of opportunistic infection-e.g., varicella zoster infection-secondary to therapies is a cause of morbidity in inflammatory bowel disease [IBD] patients. The UK vaccination schedule does not include varicella immunisation. We aimed to evaluate the varicella screening and immunisation programme in a paediatric IBD population. METHODS: Data regarding IBD diagnosis, varicella status, and consequent immunisations/treatment interventions were collected retrospectively from the records of patients diagnosed with IBD over a 10-year period [2009-2018]. RESULTS: In all, 520 IBD patients were diagnosed; 505/520 [97%] had varicella testing; 46/505 [9%] were naïve. Of 501 patients, 391[78%] were tested before or within 7 days of diagnosis; this increased in the second 5-year period compared with the first (229/268 [85%] versus 162/233 [70%]; p <0.00001). Median diagnosis age of naïve patients was lower [8.3 years versus 12.8 years; p <0.00001]. Where vaccination was feasible, 21/31 [68%] had two and 7/31 [23%] one immunisation. Prednisolone induction led to lower rates of vaccination (5/13 [39%] versus 23/33 [70%] for other induction therapies; p =0.02). Of 28 vaccinated patients, 5 [18%] had suspected breakthrough varicella; and 6/18 [33%] unimmunised patients required post-exposure prophylaxis or treatment for varicella. Immunisation was associated with a decrease in patients requiring post-exposure prophylaxis (0/28 [0%] versus 5/18 [28%]; p =0.0006) and varicella-related hospital admission (1/28 [4%] versus 4/18 [22%]; p =0.01). CONCLUSIONS: High rates of varicella screening and immunisation within a PIBD population are possible, resulting in a reduction in hospital admissions for varicella treatment. Varicella immunisation may be of increasing importance within the PIBD population with the emergence of novel therapeutic strategies.


Asunto(s)
Varicela/diagnóstico , Varicela/prevención & control , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Infecciones Oportunistas/diagnóstico , Infecciones Oportunistas/prevención & control , Vacunación/estadística & datos numéricos , Antiinflamatorios/uso terapéutico , Anticuerpos Antivirales/sangre , Varicela/sangre , Varicela/complicaciones , Niño , Femenino , Hospitalización/estadística & datos numéricos , Humanos , Huésped Inmunocomprometido , Inmunoglobulina G/sangre , Inmunosupresores/uso terapéutico , Quimioterapia de Inducción , Masculino , Infecciones Oportunistas/sangre , Infecciones Oportunistas/complicaciones , Profilaxis Posexposición/estadística & datos numéricos , Prednisolona/uso terapéutico , Estudios Retrospectivos
5.
Cad. Saúde Pública (Online) ; 36(1): e00149119, 2020. tab
Artículo en Inglés | LILACS | ID: biblio-1055626

RESUMEN

Abstract: Varicella in adults and immunocompromised patients can be severe. The clinical diagnosis of varicella has high accuracy and the history of disease has a high positive predictive value for protection. A significant portion of adults, however, cannot remember if they have had varicella, especially older individuals. We conducted a cross-sectional study to determine the seroprevalence of varicella protective antibodies titers in adults with no clinical history of disease, attended at a Reference Center for Special Immunobiologicals and Travel Medicine in Rio de Janeiro (Brazil). Titration of immunoglobulin G (IgG) antibodies to varicella-zoster was determined by chemiluminescence immunoassay. Among 140 adults without history of varicella, 92% had protective antibody titers. We concluded that seroprevalence of varicella-zoster protection was very high in adults with negative history of disease and the use of serology before vaccination reduced significantly unnecessary vaccine and immunoglobulin use.


Resumo: A varicela é uma doença potencialmente grave em adultos e em pacientes imunocomprometidos. O diagnóstico clínico da varicela apresenta alta acurácia, e o relato da doença na história individual tem alto valor preditivo positivo para a proteção. Entretanto, uma proporção significativa de adultos, principalmente os mais idosos, não se lembra se já teve a doença. Realizamos um estudo transversal para determinar a soroprevalência de títulos protetores de anticorpos contra a varicela em adultos sem história clínica da doença, atendidos em um Centro de Referência para Imunobiológicos Especiais e Medicina de Viagem no Rio de Janeiro, Brasil. Os títulos da imunoglobulina G (IgG) contra varicela-zoster foram determinados por quimiluminescência. Entre 140 adultos sem história de varicela, 92% apresentaram títulos protetores de anticorpos. Concluímos que a soroprevalência de proteção contra varicela-zoster é muito alta em adultos sem história da doença, e que o uso de teste sorológico antes da vacinação reduziria significativamente a vacinação desnecessária e o uso de imunoglobulina.


Resumen: La varicela en adultos y pacientes inmunocomprometidos puede ser grave. El diagnóstico clínico de la varicela tiene una gran precisión y la historia de la enfermedad cuenta con un alto valor predictivo positivo para la protección contra ella. Sin embargo, un porcentaje significativo de adultos, no puede recordar si tuvieron varicela, especialmente las personas más viejas. Realizamos un estudio transversal para determinar la seroprevalencia de las concentraciones de anticuerpos protectores frente a la varicela, en adultos sin historia clínica de la enfermedad, que se llevó a cabo en un Centro de Referencia para Inmunobiología Especial y Medicina del Viajero en Río de Janeiro (Brasil). Se determinó la valoración de los anticuerpos de inmunoglobulina G (IgG) a la varicela-zoster mediante un ensayo inmunológico quimioluminiscente. Entre 140 adultos sin historial de varicela, un 92% tuvieron concentraciones de anticuerpos protectores. Concluimos que la seroprevalencia de la protección a la varicela-zoster fue muy alta en adultos con un historial negativo de la enfermedad y la utilización de la serología antes de la vacunación redujo de manera significativa la vacunación innecesaria y el uso de la inmunoglobulina.


Asunto(s)
Humanos , Adulto , Inmunoglobulina G/sangre , Varicela/epidemiología , Herpesvirus Humano 3/inmunología , Brasil/epidemiología , Varicela/prevención & control , Varicela/sangre , Prevalencia , Estudios Transversales , Vacuna contra la Varicela , Mediciones Luminiscentes , Anticuerpos Antivirales/sangre
6.
Rev. esp. quimioter ; 32(6): 525-531, dic. 2019. tab, graf
Artículo en Inglés | IBECS | ID: ibc-190611

RESUMEN

INTRODUCTION: The aims of this study are to determine the seroprevalence for measles, mumps, rubella, and varicella zoster virus (VZV) in a cohort of nursing students, to evaluate vaccination response rates of nonimmune students, and to calculate the cost of vaccinating students based on seroprevalence screening. MATERIAL AND METHODS: A cross-sectional study was conducted August 2015-November 2016 among 326 healthy nursing students aged 14.1-18.1 years. Serum IgG antibodies were measured by ELISA. Results were analyzed by the Chi-square test; a p-value of < 0.05 was considered statistically significant. RESULTS: The number of seropositive participants (%) was 308 (94.5%) for rubella, 295 (90.5%) for VZV, 244 (74.9%) for measles, and 219 (67.2%) for mumps. A significant correlation was found between measles IgG and age. A relationship was also observed between VZV IgG and kindergarten attendance. Response rates to measles, rubella, VZV, and mumps vaccination were 96%, 92.3%, 87.5%, 78.8%, respectively. The total cost of vaccination after IgG screening was less than vaccination without screening. CONCLUSIONS: In this study, participants' immunity to measles and VZV was low. Prevaccination serological screening was cost-effectiveness method for preventing measles, mumps, rubella, and varicella infections. We believe that administering booster measles, mumps, and rubella (MMR) vaccine doses or developing a special MMR vaccination strategy for at-risk groups may prevent MMR outbreaks


OBJETIVOS: Los trabajadores sanitarios con frecuencia están expuestos a agentes infecciosos mientras realizan sus tareas. Los objetivos de este estudio son determinar la sero-prevalencia del virus de sarampión, paperas, rubeola y varicela zoster (VZV) en un grupo de estudiantes de enfermería, evaluar las tasas de respuesta de vacunación de estudiantes no inmunes y calcular el coste de vacunación de los estudiantes basándose en la detección de seroprevalencia. MATERIAL Y MÉTODOS: Se realizó un estudio transversal de agosto de 2015 a noviembre de 2015 entre 326 estudiantes de enfermería sanos de 14,1 a 18,1 años. Los anticuerpos IgG séricos se midieron por ELISA. Los resultados fueron analizados mediante la prueba de Chi-cuadrado. RESULTADOS: El número de participantes seropositivos (%) fue de 308 (94,5%) para la rubeola, 295 (90,5%) para el VZV, 244 (74,9%) para el sarampión y 219 (67,2%) para las paperas. Se encontró una correlación significativa entre la IgG del sarampión y la edad. También se observó una relación entre VZV IgG y asistencia a guardería. Las tasas de respuesta a la vacunación contra el sarampión, la rubeola, el VZV y las paperas fueron del 96%, 92,3%, 87,5%, 78,8%, respectivamente. El coste total de la vacunación después de la detección de IgG fue menor que la vacunación sin la detección. CONCLUSIONES: En este estudio, la inmunidad de los participantes al sarampión y al VZV fue baja. La detección serológica previa a la vacunación fue un método de coste-efectividad para prevenir las infecciones por sarampión, paperas, rubeola y varicela. Creemos que la administración de una dosis de la vacuna triple vírica de refuerzo o el desarrollo de una estrategia especial de vacunación dosis de la vacuna triple vírica para grupos en riesgo puede prevenir los brotes de de sarampión, paperas y rubeola


Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Anticuerpos Antivirales/sangre , Varicela/sangre , Varicela/epidemiología , Herpesvirus Humano 3/inmunología , Inmunoglobulina G/sangre , Sarampión/sangre , Sarampión/epidemiología , Virus del Sarampión/inmunología , Paperas/sangre , Paperas/epidemiología , Virus de la Parotiditis/inmunología , Rubéola (Sarampión Alemán)/sangre , Rubéola (Sarampión Alemán)/epidemiología , Virus de la Rubéola/inmunología , Varicela/prevención & control , Vacuna contra la Varicela , Análisis Costo-Beneficio , Estudios Transversales , Inmunogenicidad Vacunal , Sarampión/prevención & control , Vacuna contra el Sarampión-Parotiditis-Rubéola , Paperas/prevención & control , Rubéola (Sarampión Alemán)/prevención & control , Estudios Seroepidemiológicos , Estudiantes del Área de la Salud
7.
BMJ Case Rep ; 12(11)2019 Nov 28.
Artículo en Inglés | MEDLINE | ID: mdl-31780611

RESUMEN

Cryoglobulins are abnormal serum immunoglobulins that tend to precipitate in intravascular compartments at temperatures lower than 37°C causing blood flow restriction to vital organs. They are divided into type I, II and III based on the immunoglobulin subtypes of the cryoprecipitates. Type II cryoglobulinemia is most commonly associated with viral infections, autoimmune diseases and lymphoproliferative disorders. Here, we reported an 80-year-old man who presented with fatigue, acute kidney injury, palpable purpura, anaemia and altered mental status. He was diagnosed with type II cryoglobulinemia with concomitant positive autoimmune markers, varicella IgM antibody and IgM hepatitis B core antibody. The patient responded well to intravenous and oral steroid treatment.


Asunto(s)
Enfermedades Autoinmunes/complicaciones , Varicela/complicaciones , Crioglobulinemia/complicaciones , Hepatitis B/complicaciones , Anciano de 80 o más Años , Enfermedades Autoinmunes/sangre , Biomarcadores/sangre , Varicela/sangre , Crioglobulinemia/sangre , Crioglobulinemia/clasificación , Hepatitis B/sangre , Humanos , Masculino
8.
Rev Esp Quimioter ; 32(6): 525-531, 2019 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-31642641

RESUMEN

OBJECTIVE: The aims of this study are to determine the seroprevalence for measles, mumps, rubella, and varicella zoster virus (VZV) in a cohort of nursing students, to evaluate vaccination response rates of nonimmune students, and to calculate the cost of vaccinating students based on seroprevalence screening. METHODS: A cross-sectional study was conducted August 2015-November 2016 among 326 healthy nursing students aged 14.1-18.1 years. Serum IgG antibodies were measured by ELISA. Results were analyzed by the Chi-square test; a p-value of < 0.05 was considered statistically significant. RESULTS: The number of seropositive participants (%) was 308 (94.5%) for rubella, 295 (90.5%) for VZV, 244 (74.9%) for measles, and 219 (67.2%) for mumps. A significant correlation was found between measles IgG and age. A relationship was also observed between VZV IgG and kindergarten attendance. Response rates to measles, rubella, VZV, and mumps vaccination were 96%, 92.3%, 87.5%, 78.8%, respectively. The total cost of vaccination after IgG screening was less than vaccination without screening. CONCLUSIONS: In this study, participants' immunity to measles and VZV was low. Prevaccination serological screening was cost-effectiveness method for preventing measles, mumps, rubella, and varicella infections. We believe that administering booster measles, mumps, and rubella (MMR) vaccine doses or developing a special MMR vaccination strategy for at-risk groups may prevent MMR outbreaks.


Asunto(s)
Anticuerpos Antivirales/sangre , Varicela/sangre , Varicela/epidemiología , Herpesvirus Humano 3/inmunología , Inmunoglobulina G/sangre , Virus del Sarampión/inmunología , Sarampión/sangre , Sarampión/epidemiología , Virus de la Parotiditis/inmunología , Paperas/sangre , Paperas/epidemiología , Virus de la Rubéola/inmunología , Rubéola (Sarampión Alemán)/sangre , Rubéola (Sarampión Alemán)/epidemiología , Adolescente , Varicela/prevención & control , Vacuna contra la Varicela , Análisis Costo-Beneficio , Estudios Transversales , Femenino , Humanos , Inmunogenicidad Vacunal , Masculino , Sarampión/prevención & control , Vacuna contra el Sarampión-Parotiditis-Rubéola , Paperas/prevención & control , Rubéola (Sarampión Alemán)/prevención & control , Estudios Seroepidemiológicos , Estudiantes del Área de la Salud
9.
Mod Rheumatol ; 29(3): 558-562, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-27846755

RESUMEN

We report the clinical course and outcome of primary varicella infection in six children with systemic juvenile idiopathic arthritis (sJIA) receiving tocilizumab. None had disseminated or fatal varicella infection, but one patient developed macrophage activation syndrome (MAS) and another had an arthritis relapse. All patients had a significant elevation of serum IL-6 levels, and the two children who developed MAS or arthritis relapse showed high serum IL-18 levels, which could cause a sJIA flare-up.


Asunto(s)
Anticuerpos Monoclonales Humanizados/efectos adversos , Artritis Juvenil/complicaciones , Varicela/patología , Inmunosupresores/efectos adversos , Síndrome de Activación Macrofágica/patología , Anticuerpos Monoclonales Humanizados/uso terapéutico , Artritis Juvenil/tratamiento farmacológico , Varicela/sangre , Varicela/etiología , Niño , Femenino , Humanos , Inmunosupresores/uso terapéutico , Interleucina-18/sangre , Síndrome de Activación Macrofágica/sangre , Síndrome de Activación Macrofágica/etiología , Masculino
10.
Stat Methods Med Res ; 28(10-11): 3437-3450, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30319043

RESUMEN

Frailty models have been developed to quantify both heterogeneity as well as association in multivariate time-to-event data. In recent years, numerous shared and correlated frailty models have been proposed in the survival literature allowing for different association structures and frailty distributions. A bivariate correlated gamma frailty model with an additive decomposition of the frailty variables into a sum of independent gamma components was introduced before. Although this model has a very convenient closed-form representation for the bivariate survival function, the correlation among event- or subject-specific frailties is bounded above which becomes a severe limitation when the values of the two frailty variances differ substantially. In this article, we review existing correlated gamma frailty models and propose novel ones based on bivariate gamma frailty distributions. Such models are found to be useful for the analysis of bivariate survival time data regardless of the censoring type involved. The frailty methodology was applied to right-censored and left-truncated Danish twins mortality data and serological survey current status data on varicella zoster virus and parvovirus B19 infections in Belgium. From our analyses, it has been shown that fitting more flexible correlated gamma frailty models in terms of the imposed association and correlation structure outperforms existing frailty models including the one with an additive decomposition.


Asunto(s)
Varicela/epidemiología , Modelos Estadísticos , Mortalidad/tendencias , Infecciones por Parvoviridae/epidemiología , Análisis de Supervivencia , Estudios en Gemelos como Asunto , Bélgica/epidemiología , Varicela/sangre , Dinamarca/epidemiología , Femenino , Humanos , Masculino , Análisis Multivariante , Infecciones por Parvoviridae/sangre , Parvovirus B19 Humano
11.
BMC Infect Dis ; 18(1): 563, 2018 Nov 14.
Artículo en Inglés | MEDLINE | ID: mdl-30428851

RESUMEN

BACKGROUND: In recent years, outbreaks of varicella have continued to occur, and the coverage rate of varicella vaccine in Jiangsu Province, China, remains unclear. This study aims to analyse the levels of immune antibody against varicella and obtain a comprehensive understanding of the varicella attenuated live vaccine (VarV) coverage rate in children aged 1-9 years in Jiangsu Province. METHODS: From June to October 2016, a cross-sectional survey was conducted to collect 3631 serum samples from healthy children aged 1-9 years in Jiangsu Province. The immunoglobulin G (IgG) antibody levels of varicella were detected by enzyme-linked immunosorbent assay (ELISA). RESULTS: The VarV coverage rate of healthy children was only 43.1% (95% CI: 41.1-44.7%). The seroprevalence after vaccination with a single dose of VarV was only 57.1%, and the overall seropositivity and geometric antibody titre (GMC) were 43.5% and 225.4 mU/ml, respectively. The seropositivity was significantly higher in girls than in boys (χ2 = 18.82, P < 0.001). The difference in seropositivity between the 5-9 age group and 1-4 age group was statistically significant (χ2 = 84.31, P < 0.001). The difference in seropositivity between different regions was statistically significant, with the highest seropositivity in the northern area, 53.7% (χ2 = 35.64, P < 0.001). The seropositivity in the group receiving one dose of VarV was significantly higher than that of the unvaccinated group (χ2 = 205.16, P < 0.001). Linear regression analysis suggested that the GMC of varicella antibodies wanes with the time since vaccination (F = 65.01, P = 0.002). CONCLUSION: The VarV coverage rate of healthy children in Jiangsu Province was low. Sero-conversion rates were also low after one dose of VarV, and the immune effectiveness of a single dose of VarV was limited. To control the spread of varicella, VarV should be included in the routine immunization program, and strengthened immunization measures for the varicella-susceptible population warrant additional consideration.


Asunto(s)
Anticuerpos Antivirales/sangre , Infecciones Asintomáticas/epidemiología , Varicela/sangre , Varicela/epidemiología , Herpesvirus Humano 3/inmunología , Varicela/prevención & control , Vacuna contra la Varicela/uso terapéutico , Niño , Preescolar , China/epidemiología , Estudios Transversales , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Programas de Inmunización , Lactante , Masculino , Estudios Seroepidemiológicos , Vacunación/estadística & datos numéricos , Vacunas Atenuadas/uso terapéutico
13.
Swiss Med Wkly ; 146: w14342, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27585235

RESUMEN

QUESTION UNDER STUDY: In Switzerland, vaccination against varicella is not recommended in the basic immunisation schedule. However, for individuals aged 11-40 years who do not have a reliable varicella history the Swiss Federal Office of Public Health recommends either (i) a vaccination or (ii) a serology test and vaccination of those with a negative result. In the Travel Clinic of the University of Zurich, the second strategy is followed. In this study we retrospectively assessed the overall percentage of individuals with varicella-specific antibodies despite a negative history and we examined the influence of age, number of siblings, order of siblings, age difference to siblings and nationality on varicella seropositivity. METHODS: Between December 2008 and August 2015, the sera of 1757 individuals with a negative varicella history were tested for varicella antibodies. RESULTS: A total of 1593 individuals (91%) had a positive result. We found an increasing trend for varicella seropositivity with increasing age. Those aged less than 40 years were significantly more often seronegative (9.5%) than those aged 40 years and above (6.0%, p = 0.049). Seropositivity was associated with nationality. The percentage of seropositives increased with the number of siblings. CONCLUSIONS: Our results indicate that, despite the significant varicella seropositivity differences between those aged below and above, the age of 40 may not be an ideal threshold for performing a varicella serology in individuals with a negative or unknown varicella history. In the age groups above 40, testing for varicella antibodies may be especially reasonable in individuals with no or a small number of siblings and in those of specific nationalities.


Asunto(s)
Instituciones de Atención Ambulatoria , Varicela/epidemiología , Estudios Seroepidemiológicos , Medicina del Viajero , Vacunación , Adulto , Factores de Edad , Anticuerpos Antivirales/sangre , Varicela/sangre , Femenino , Herpesvirus Humano 3/aislamiento & purificación , Humanos , Masculino , Anamnesis , Estudios Retrospectivos , Pruebas Serológicas/métodos , Encuestas y Cuestionarios , Suiza
14.
Aust N Z J Public Health ; 40(3): 284-9, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27027875

RESUMEN

OBJECTIVE: To determine seroprotection for the vaccine-preventable diseases (VPDs) measles, mumps, rubella, varicella and hepatitis B among new employees seen at a Victorian tertiary hospital staff clinic. METHODS: Employees who presented to the staff clinic for immunisation assessment between 1 January 2012 and 31 December 2013 were included. Demographic data, self-reported disease history and previous vaccination status were reviewed retrospectively to determine impact on serological results. RESULTS: A total of 1,901 new employees were included, 83% of whom were at risk of direct contact with blood or body substances. Overall, the proportion of workers seropositive to measles was 88%, mumps 90%, rubella 78%, varicella 93% and hepatitis B 80%. Staff born before 1966 were more likely to have positive measles or mumps serology but negative rubella or hepatitis B serology (p<0.05 for each). Staff who self-reported measles (99% vs. 93%, p=0.03) or varicella infection (98% vs. 92%, p<0.001) were more likely to be seropositive, but those reporting previous vaccination to measles, mumps or rubella were no more likely to be seropositive. CONCLUSIONS AND IMPLICATIONS: This study demonstrated levels of seropositivity of 78-93% for the five VPDs. Despite recognised limitations of serological testing, 10-20% of new employees to a healthcare institution lacking seroprotection represents a potentially unacceptable risk of nosocomial transmission of these VPDs. Our findings support ongoing serological testing of new healthcare staff at risk of direct contact with blood or body substances.


Asunto(s)
Anticuerpos Antivirales/sangre , Varicela/sangre , Infección Hospitalaria/prevención & control , Hepatitis B/sangre , Infecciones por Virus ARN/sangre , Adulto , Varicela/epidemiología , Varicela/prevención & control , Infección Hospitalaria/sangre , Femenino , Personal de Salud , Hepatitis B/epidemiología , Hepatitis B/prevención & control , Humanos , Masculino , Persona de Mediana Edad , Infecciones por Virus ARN/epidemiología , Infecciones por Virus ARN/prevención & control , Estudios Seroepidemiológicos , Centros de Atención Terciaria , Vacunación , Victoria/epidemiología
15.
J Dermatol ; 42(8): 795-9, 2015 08.
Artículo en Inglés | MEDLINE | ID: mdl-25916861

RESUMEN

Varicella is a highly contagious infection caused by varicella zoster virus. Sometimes it is difficult to differentiate between other viral infections such as Kaposi's varicelliform eruption (KVE) and disseminated herpes zoster (HZ). The large unstained cells (LUC) value is a differential count parameter reported by routing hematology analysis. LUC have been studied previously, but never been reported in the context of varicella or in dermatological published work. The aim of this study was to compare the LUC values in varicella patients with that in KVE and disseminated HZ patients. Sixty-nine varicella patients, 30 KVE patients and 11 disseminated HZ patients were included in this retrospective study. All data were analyzed using SPSS version 17.0 or GraphPad Prism version 5.0. The mean percentage of LUC (%LUC) in varicella patients was higher than the upper limit of normal reference range and it was increased compared to %LUC of both KVE (P < 0.0001) and disseminated HZ (P = 0.0051) patients. %LUC of varicella patients significantly decreased with clinical improvements (P = 0.0017). %LUC was significantly increased in varicella patients and corresponded with clinical improvements. Patients with %LUC of 3.55 or more favor the diagnosis of varicella over both KVE and disseminated HZ with 71.01% sensitivity and 84.44% specificity. We suggest that %LUC can assist in making a precise diagnosis of varicella in confusing cases.


Asunto(s)
Varicela/diagnóstico , Adulto , Recuento de Células Sanguíneas , Varicela/sangre , Diagnóstico Diferencial , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Adulto Joven
16.
Blood Coagul Fibrinolysis ; 25(3): 277-9, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24253242

RESUMEN

We describe the case of a 3-year-old girl, admitted to the pediatric ward for three repeated episodes of severe migraine associated with vertigo, with onset 1 week after complete remission from an episode of chicken pox (i.e., varicella-zoster virus infection). All radiological and laboratory examinations were normal, except for a markedly elevated value of D-dimer (i.e. 8998 ng/ml; local reference range: < 243 ng/ml), measured with a commercial latex-enhanced immunoturbidimetric assay. After physical and Doppler ultrasound examination, possible presence of thrombosis was ruled out, and the patient was discharged. In the following year, however, her plasma D-dimer values always remained frankly elevated, so that an analytical interference was suspected. A plasma sample was treated with a specific heterophilic antibodies blocking reagent and then assayed along with the untreated sample, with these showing a marked discrepancy of D-dimer values, that is 232 versus 2877 ng/ml. These results, highly indicative for the presence of heterophilic antibodies, are discussed in the light of the serious challenges that this type of analytical interference may pose on quality and reliability of D-dimer testing.


Asunto(s)
Anticuerpos Heterófilos/sangre , Varicela/sangre , Productos de Degradación de Fibrina-Fibrinógeno/metabolismo , Trastornos Migrañosos/sangre , Vértigo/sangre , Preescolar , Femenino , Humanos , Trombosis Intracraneal/sangre , Trombosis Intracraneal/diagnóstico , Trastornos Migrañosos/virología , Valores de Referencia , Reproducibilidad de los Resultados , Vértigo/virología
17.
Eur Rev Med Pharmacol Sci ; 17(15): 2032-9, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23884823

RESUMEN

BACKGROUND: Chicken pox is commonly known as a benign exenthamatous disease of childhood, occasionally neurologic or hemorrhagic complications, or even death may ensue. Early predictors of severity of disease have yet to be identified. TNF-alpha and IL-6 stimulate virus-specific immunoglobulin production and it has been postulated that determination of levels of these cytokines may be useful as a prognostic factor. PATIENTS AND METHODS: Patients who were diagnosed with a varicella-zoster virus (VZV) infection in the Outpatient Clinic of the Department of Pediatric Infectious Diseases were evaluated for eligibility. Laboratory assays included an evaluation of complete blood counts, erythrocyte-sedimentation rate (ESR), c reactive protein (CRP), and the number of tumor necrosis factor-alpha/interleukin-6-(TNF-alpha/IL-6-) producing mononuclear cells as determined by flow cytometry. RESULTS: A total of 339 patients (320 with chickenpox and 19 with shingles) were enrolled. Blood samples could only be obtained from 81 of the 320 patients with chickenpox. Patients were also divided into three groups depending on the number of skin (vesicular) lesions. (group 1, ≤ 50 lesions; group 2, 51-100 lesions; group 3, >100 lesions). Correlation analyses did not reveal the presence of a statistically significant correlation between number of skin lesions with either of white blood cells (WBC) count (p = 0.231), ESR (p = 0.879) or CRP (p = 0.373). The mean percentage of TNF-alpha-producing mononuclear cells was significantly higher in group 2 compared to group 3 (p = 0.003). A similar difference was observed with regard to IL-6-producing mononuclear cells, albeit bordering on statistical significance (p = 0.058). CONCLUSIONS: Decreased expression of the cytokines TNF-alpha and IL-6 may be responsible for the development of a more severe clinical picture in patients with VZV infection, and determination of intracellular levels of these cytokines may be of benefit for early identification of patients who may have a more severe clinical course.


Asunto(s)
Varicela/sangre , Herpes Zóster/sangre , Interleucina-6/sangre , Factor de Necrosis Tumoral alfa/sangre , Adolescente , Biomarcadores/sangre , Varicela/diagnóstico , Vacuna contra la Varicela , Niño , Preescolar , Femenino , Herpes Zóster/diagnóstico , Humanos , Lactante , Inflamación/sangre , Leucocitos Mononucleares/metabolismo , Masculino , Pronóstico
18.
J Int Med Res ; 41(1): 224-30, 2013 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-23569149

RESUMEN

OBJECTIVE: Seroprevalence surveys of healthcare workers for vaccine-preventable diseases, including measles and varicella, are essential for disease prevention and infection control programmes. The purpose of this study was to compare the complement fixation (CF) assay and an enzyme immunoassay (EIA) to determine the prevalence of immunoglobulin G antibodies directed against measles and varicella viruses in healthcare workers. METHODS: Antimeasles and antivaricella antibody titres were measured simultaneously in serum samples from healthcare workers employed at a Japanese university hospital, using the CF assay and an EIA. RESULTS: Serum samples were obtained from 898 healthcare workers. Seropositivity rates determined using the CF assay and EIA were 67.8% versus 94.0%, respectively, for measles, and 83.2% versus 97.6% for varicella. Compared with EIA, a nine- and 22-fold higher number of seronegative subjects was identified by the CF assay for measles and varicella, respectively. CONCLUSION: Differences between the CF assay and EIA in detecting seronegative or seropositive healthcare workers for measles and varicella suggest that undertaking a seroprevalence survey using an EIA, rather than a CF assay, would more accurately determine susceptibility to vaccine-preventable diseases, in healthcare settings.


Asunto(s)
Varicela/sangre , Varicela/epidemiología , Pruebas de Fijación del Complemento , Personal de Salud/estadística & datos numéricos , Encuestas Epidemiológicas/estadística & datos numéricos , Técnicas para Inmunoenzimas , Sarampión/epidemiología , Adulto , Anciano , Varicela/inmunología , Femenino , Humanos , Inmunoglobulina G/sangre , Japón/epidemiología , Masculino , Sarampión/sangre , Sarampión/inmunología , Persona de Mediana Edad , Estudios Seroepidemiológicos , Adulto Joven
19.
Hematology ; 18(2): 119-22, 2013 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-23321260

RESUMEN

From 2005 to 2011, 25 children of both sexes (13 boys and 12 girls, mean age 7.8 ± 2.5 years, 5-12.4 years) with acute varicella zoster virus (VZV) infection were selected. Five patients showed venous thromboembolism characterized by deep venous thrombosis (DVT). Comparison of activated partial thromboplastin time, antithrombin III, D-dimer, lupus anticoagulant, free S protein (PS), C protein, and antiphospholipid and PS antibodies was performed on children with acute VZV and DVT (group I), acute uncomplicated VZV (group II), and 30 healthy controls of both sexes (15 boys and 15 girls, mean age 7.5 ± 2.6 years, group III). Genetic thrombophilic mutations (Factor V Leiden, MTHFR C677T, and Prothrombin G20210A) were evaluated. Coagulation disorders and PS antibody were found in children with acute VZV (groups I and II). Significant differences were shown among the three groups (P < 0.05). Acute VZV infection could be associated with coagulation disorders and production of inhibitory PS antibodies in many uncomplicated cases.


Asunto(s)
Varicela/sangre , Trombofilia/sangre , Trombofilia/genética , Anticuerpos Antifosfolípidos/análisis , Antitrombina III/análisis , Autoanticuerpos/análisis , Varicela/complicaciones , Varicela/virología , Niño , Preescolar , Factor V/genética , Femenino , Productos de Degradación de Fibrina-Fibrinógeno/análisis , Herpesvirus Humano 3/fisiología , Humanos , Inhibidor de Coagulación del Lupus/análisis , Masculino , Metilenotetrahidrofolato Reductasa (NADPH2)/genética , Mutación , Tiempo de Tromboplastina Parcial , Proteína C/análisis , Proteína S/análisis , Proteína S/inmunología , Protrombina/genética , Medición de Riesgo , Factores de Riesgo , Trombofilia/complicaciones , Tromboembolia Venosa/sangre , Tromboembolia Venosa/etiología , Tromboembolia Venosa/genética , Trombosis de la Vena/sangre , Trombosis de la Vena/etiología , Trombosis de la Vena/genética
20.
Ceylon Med J ; 58(4): 153-6, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-24385056

RESUMEN

INTRODUCTION: Genotyping of wild type of varicella zoster virus (VZV) in Sri Lanka would help to distinguish the VZV wild type infection from varicella vaccine associated infections. METHODS: PCR-RFLP analysis of VZV ORF 38, 54 and 62 was used for genotyping in VZV from blood or vesicular fluid from 31 patients with chickenpox or herpes zoster. The PstI restriction site of ORF 38, BglI restriction site of ORF 54 and SmaI restriction site of ORF 62 were analyzed using RFLP to determine the genotype. RESULTS: Except for one strain, all other VZV isolates had the genotype characteristic of the wild type VZV strain PstI+BglI+ SmaI-, which was characteristic of the Asian strain. None of the isolates had the American or the European VZV profile (PstI+BglI-) but were similar to isolates from Africa and Asia (PstI+BglI+). Interestingly, one of the VZV strains isolated from a patient with chickenpox had the characteristic genotype of the vaccine strain PstI- BglI+ SmaI+. CONCLUSIONS: The genotype of the VZV in Sri Lanka is similar to the Asian VZV genotype and can be easily distinguished from the VZV vaccine strain by using the polymorphisms in ORF 38, ORF 54 and ORF 62.


Asunto(s)
Varicela/virología , Herpes Zóster/virología , Herpesvirus Humano 3/genética , Proteínas Virales/genética , Varicela/sangre , Vacuna contra la Varicela/efectos adversos , Desoxirribonucleasas de Localización Especificada Tipo II , Genotipo , Herpes Zóster/sangre , Humanos , Reacción en Cadena de la Polimerasa , Polimorfismo de Longitud del Fragmento de Restricción , Sri Lanka
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...